Please wait a minute...
浙江大学学报（医学版）
浙江大学学报（医学版）  2018, Vol. 47 Issue (5): 552-557    DOI: 10.3785/j.issn.1008-9292.2018.10.16
综述     
CCAAT增强子结合蛋白α与急性髓细胞白血病的发生
史庭(),叶琇锦*()
浙江大学医学院附属第一医院血液科, 浙江 杭州 310003
Roles of CCAAT enhancer binding protein α in acute myeloblastic leukemia
SHI Ting(),YE Xiujin*()
Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
 全文: PDF(891 KB)   HTML( 6 )
摘要：

CCAAT增强子结合蛋白α（C/EBPα）在髓系造血过程中起着重要的调控作用，其基因表达失调是急性髓细胞白血病（AML）发生的重要机制。C/EBPα基因表达失控的结局是p30过表达和p42不完全丧失，两者均促使AML的发生。因此，恢复C/EBPα表达比例，过表达p42或阻断p30致癌通路是治疗此类原因所致AML的重要途径。本文回顾了近年来关于C/EBPα表达失调及其两种蛋白体在AML发病机制中的研究进展。
关键词： CCAAT增强子结合蛋白α;  白血病, 髓样, 急性;  基因表达;  突变;  综述    
Abstract:

The CCAAT enhancer binding protein α (C/EBP α:p42 and p30), which encoded by CCAAT enhancer binding protein α (C/EBPα) gene, plays a pretty crucial role in the regulation of myeloid hematopoiesis.The disorder of CEBPA gene expression is an pivotal mechanism of acute myeloid leukemia (AML). The result of uncontrolled expression of C/EBP α gene is the over-expression of p30 and the incomplete loss of p42, both of which contribute to the occurrence of AML. Restoring the expression ratio of C/EBP α such as over-expression of p42 or blocking the carcinogenic pathway of p30 seems to be important for the treatment of AML caused by such causes. In order to better guide medical decision-making, this article reviews research progress on C/EBPα in the pathogenesis of AML.
Key words: CCAAT enhancer binding protein α    Leukemia, myeloid, acute    Gene expression    Mutation    Review
收稿日期: 2018-04-18 出版日期: 2019-01-23
:  R733.71  
基金资助: 浙江省科技计划(2016C33137);浙江省医药卫生科技计划(2017KY059)
通讯作者: 叶琇锦     E-mail: 1626293723@qq.com;yxjsunny@zju.edu.cn
作者简介: 史庭(1992-), 女, 硕士研究生, 主要从事血液系统疾病研究; E-mail:1626293723@qq.com; https://orcid.org/0000-0002-8031-1778
服务　　
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章　　
史庭
叶琇锦

引用本文:

史庭,叶琇锦. CCAAT增强子结合蛋白α与急性髓细胞白血病的发生[J]. 浙江大学学报（医学版）, 2018, 47(5): 552-557.

SHI Ting,YE Xiujin. Roles of CCAAT enhancer binding protein α in acute myeloblastic leukemia. J Zhejiang Univ (Med Sci), 2018, 47(5): 552-557.

链接本文:

http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2018.10.16    或    http://www.zjujournals.com/med/CN/Y2018/V47/I5/552

1 AVELLINO R , DELWEL R . Expression and regulation of C/EBPα in normal myelopoiesis and in malignant transformation[J]. Blood, 2017, 129 (15): 2083- 2091
doi: 10.1182/blood-2016-09-687822
2 PULIKKAN J A , TENEN D G , BEHRE G . C/EBPα deregulation as a paradigm for leukemogenesis[J]. Leukemia, 2017, 31 (11): 2279- 2285
doi: 10.1038/leu.2017.229
3 PULIKKAN J A , DENGLER V , PERAMANGALAM P S et al. Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia[J]. Blood, 2010, 115 (9): 1768- 1778
doi: 10.1182/blood-2009-08-240101
4 PULIKKAN J A , PERAMANGALAM P S , DENGLER V et al. C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations[J]. Blood, 2010, 116 (25): 5638- 5649
doi: 10.1182/blood-2010-04-281600
5 FASAN A , HAFERLACH C , ALPERMANN T et al. The role of different genetic subtypes of CEBPA mutated AML[J]. Leukemia, 2014, 28 (4): 794- 803
doi: 10.1038/leu.2013.273
6 CALKHOVEN C F , MA LLER C , LEUTZ A . Translational control of C/EBPalpha and C/EBPbeta isoform expression[J]. Genes Dev, 2000, 14 (15): 1920- 1932
7 OHLSSON E , SCHUSTER M B , HASEMANN M et al. The multifaceted functions of C/EBPα in normal and malignant haematopoiesis[J]. Leukemia, 2016, 30 (4): 767- 775
doi: 10.1038/leu.2015.324
8 PABST T , MUELLER B U . Transcriptional dysregulation during myeloid transformation in AML[J]. Oncogene, 2007, 26 (47): 6829- 6837
doi: 10.1038/sj.onc.1210765
9 FASAN A, ALPERMANN T, HAFERLACH C, et al. Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 cases[J/OL]. PLoS One, 2013, 8(2): e54365.
10 MUSIALIK E , BUJKO M , KOBER P et al. Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT/enhancer binding proteins in AML patients[J]. Leuk Res, 2014, 38 (7): 850- 856
doi: 10.1016/j.leukres.2014.04.013
11 SANTANA-LEMOS B A , DE LIMA LANGE A P , DE LIRA BENⅡCIO M T et al. The CEBPA gene is down-regulated in acute promyelocytic leukemia and its upstream promoter, but not the core promoter, is highly methylated[J]. Haematologica, 2011, 96 (4): 617- 620
doi: 10.3324/haematol.2010.028365
12 RADOMSKA H S , BASSERES D S , ZHENG R et al. Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations[J]. J Exp Med, 2006, 203 (2): 371- 381
doi: 10.1084/jem.20052242
13 RADOMSKA H S , ALBERICH-JORDA M , WILL B et al. Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα[J]. J Clin Invest, 2012, 122 (8): 2955- 2966
doi: 10.1172/JCI43354
14 BARARIA D , KWOK H S , WELNER R S et al. Acetylation of C/EBPα inhibits its granulopoietic function[J]. Nat Commun, 2016, 7:10968
doi: 10.1038/ncomms10968
15 HEDGE V L , TOMAR S , JACKSON A et al. Distinct microRNA expression profile and targeted biological pathways in functional myeloid-derived suppressor cells induced by Δ9-tetrahydrocannabinol in vivo:regulation of CCAAT/enhancer-binding protein α by microRNA-690[J]. J Biol Chem, 2013, 288 (52): 36810- 36826
doi: 10.1074/jbc.M113.503037
16 LOKE J , CHIN P S , KEANE P et al. C/EBPα overrides epigenetic reprogramming by oncogenic transcription factors in acute myeloid leukemia[J]. Blood Adv, 2018, 2 (3): 271- 284
doi: 10.1182/bloodadvances.2017012781
17 NERLOV C . C/EBP alpha mutations in acute myeloid leukaemias[J]. Nat Rev Cancer, 2004, 4 (5): 394- 400
doi: 10.1038/nrc1363
18 ZHANG P , IWASAKI-ARAI J , IWASAKI H et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha[J]. Immunity, 2004, 21 (6): 853- 863
doi: 10.1016/j.immuni.2004.11.006
19 WAGNER K , ZHANG P , ROSENBAUER F et al. Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy[J]. Proc Natl Acad Sci U S A, 2006, 103 (16): 6338- 6343
doi: 10.1073/pnas.0508143103
20 CALKHOVEN C F , MULLER C , LEUTZ A . Translational control of C/EBPalpha and C/EBPbeta isoform expression[J]. Genes Dev, 2000, 14 (15): 1920- 1932
21 WEI S , KOZONO S , KATS L et al. Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer[J]. Nat Med, 2015, 21 (5): 457- 466
doi: 10.1038/nm.3839
22 LIAN X , LIN Y M , KOZONO S et al. Correction to:Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways[J]. J Hematol Oncol, 2018, 11 (1): 94
doi: 10.1186/s13045-018-0634-0
23 PULIKKAN J A , DENGLER V , PEER ZADA A A et al. Elevated PIN1 expression by C/EBP alpha-p30 blocks C/EBPalpha-induced granulocytic differentiation through c-Jun in AML[J]. Leukemia, 2010, 24 (5): 914- 923
doi: 10.1038/leu.2010.37
24 RISHI L , HANNON M , SALOME M et al. Regulation of Trib2 by an E2F1-C/EBPα feedback loop in AML cell proliferation[J]. Blood, 2014, 123 (15): 2389- 2400
doi: 10.1182/blood-2013-07-511683
25 LAMMENS T , DURINCK K , WALLAERT A et al. Long non-coding RNAs in leukemia:biology and clinical impact[J]. Curr Opin Hematol, 2017, 24 (4): 353- 358
doi: 10.1097/MOH.0000000000000354
26 PAPIAOANNOU D , NICOLET D , VOLINIA S et al. Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia[J]. Haematologica, 2017, 102 (8): 1391- 1400
doi: 10.3324/haematol.2017.166215
27 黄禾菁, 侯健 . SUMO化修饰与血液系统疾病[J]. 中国实验血液学杂志, 2013, 21 (1): 218- 221
HUANG Hejing , HOU Jian . SUMOylation and its role in hematological disease[J]. Journal of Experimental Hematology, 2013, 21 (1): 218- 221
28 GELETU M , BALKHI M Y , PEER ZADA A A et al. Target proteins of C/EBPalphap30 in AML:C/EBPalphap30 enhances sumoylation of C/EBPalphap42 via up-regulation of Ubc9[J]. Blood, 2007, 110 (9): 3301- 3309
doi: 10.1182/blood-2007-01-071035
29 HANKEY W, SILVER M, SUN B S, et al. Differential effects of sumoylation on the activities of CCAAT enhancer binding protein alpha (C/EBPα) p42 versus p30 may contribute in part, to aberrant C/EBPα activity in acute leukemias[J/OL]. Hematol Rep, 2011, 3(1): e5.
30 黎彦璟, 陈勇 . 组蛋白甲基转移酶MLL1的结构与功能研究进展[J]. 中国细胞生物学学报, 2014, (7): 857- 868
LI Yanjing , CHEN Yong . Progress in structural and functional studies of histone methyltransferase MLL1[J]. Chinese Journal of Cell Biology, 2014, 36 (7): 857- 868
31 GREBIEN F , VEDADI M , GETLIK M et al. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia[J]. Nat Chem Biol, 2015, 11 (8): 571- 578
doi: 10.1038/nchembio.1859
32 THIEL A T , BLESSINGTON P , ZOU T et al. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele[J]. Cancer Cell, 2010, 17 (2): 148- 159
doi: 10.1016/j.ccr.2009.12.034
33 OHLSSON E , HASEMANN M S , WILLER A et al. Initiation of MLL-rearranged AML is dependent on C/EBPα[J]. J Exp Med, 2014, 211 (1): 5- 13
doi: 10.1084/jem.20130932
34 COLLINS C , WANG J , MIAO H et al. C/EBPα is an essential collaborator in Hoxa9/Meis1-mediated leukemogenesis[J]. Proc Natl Acad Sci U S A, 2014, 111 (27): 9899- 9904
doi: 10.1073/pnas.1402238111
35 O'CONNOR C , LOHAN F , CAMPOS J et al. The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia[J]. Oncogene, 2016, 35 (40): 5272- 5281
doi: 10.1038/onc.2016.66
36 YE M , ZHANG H , YANG H et al. Hematopoietic differentiation is required for initiation of acute myeloid leukemia[J]. Cell Stem Cell, 2015, 17 (5): 611- 623
doi: 10.1016/j.stem.2015.08.011
37 ROE J S , VAKOC C R . C/EBPα:critical at the origin of leukemic transformation[J]. J Exp Med, 2014, 211 (1): 1- 4
doi: 10.1084/jem.20132530
38 刘爱飞, 王金霞, 李方林 et al. miR-125在恶性血液疾病中的研究进展[J]. 中国实验血液学杂志, 2017, 25 (6): 1842- 1846
LIU Aifei , WANG Jinxia , LI Fanglin et al. Research progress on miR-125 family in malignant hematologic diseases[J]. Journal of Experimental Hematology, 2017, 25 (6): 1842- 1846
39 VARGAS Romero P , CIALFI S , PALERMO R et al. The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBPα[J]. Leukemia, 2015, 29 (12): 2442- 2445
doi: 10.1038/leu.2015.117
[1] 赵慧慧, 汤慧芳. 基于基因敲除的炎性肠疾病复合动物模型研究进展[J]. 浙江大学学报（医学版）, 2018, 47(6): 665-670.
[2] 曹丽芹, 施继敏. 异基因造血干细胞移植植入失败研究进展[J]. 浙江大学学报（医学版）, 2018, 47(6): 651-658.
[3] 唐和孝, 白玉泉, 申武林, 赵金平. 白介素6在肺癌中的作用研究进展[J]. 浙江大学学报（医学版）, 2018, 47(6): 659-664.
[4] 尹黎, 李歌, 沈健, 刘震杰. 遗传性易栓症筛查及相关基因检测分析[J]. 浙江大学学报（医学版）, 2018, 47(6): 606-611.
[5] 向一郎, 吴子衡, 张鸿坤. 胸主动脉覆膜支架原位开窗技术的应用现状[J]. 浙江大学学报（医学版）, 2018, 47(6): 617-622.
[6] 李高鹏,何佳,王青青. 肿瘤相关成纤维细胞对肿瘤免疫调控作用的研究进展[J]. 浙江大学学报（医学版）, 2018, 47(5): 558-563.
[7] 叶建宇,孙自玉,胡薇薇. 星形胶质细胞在脑梗死中的作用及相关治疗策略[J]. 浙江大学学报（医学版）, 2018, 47(5): 493-498.
[8] 王晓玲,欧阳旭梅,孙晓译. 基于间充质干细胞的小分子化学药物肿瘤靶向递送系统研究进展[J]. 浙江大学学报（医学版）, 2018, 47(5): 525-533.
[9] 胡彩琴,朱彪. 进行性多灶性脑白质病的发病机制研究进展[J]. 浙江大学学报（医学版）, 2018, 47(5): 534-540.
[10] 何佳怡,张信美. 氧化应激在子宫内膜异位症发病机制中的研究进展[J]. 浙江大学学报（医学版）, 2018, 47(4): 419-425.
[11] 徐至理,崔一怡,李妍,郭勇. 乳腺癌非特异性免疫微环境的研究进展[J]. 浙江大学学报（医学版）, 2018, 47(4): 426-434.
[12] 王星星,王盼盼,杨旭燕. 系统性红斑狼疮合并器官特异性自身免疫性疾病的相关研究进展[J]. 浙江大学学报（医学版）, 2018, 47(4): 435-440.
[13] 张丽凤,张信美. 维生素D在子宫内膜异位症中的作用研究进展[J]. 浙江大学学报（医学版）, 2018, 47(4): 413-418.
[14] 钱波,张彦玲,莫绪明. 先天性食管闭锁相关转录因子及信号通路研究进展[J]. 浙江大学学报（医学版）, 2018, 47(3): 239-243.
[15] 张小燕,康利军. 秀丽隐杆线虫嗅觉适应性的分子细胞生物学机制[J]. 浙江大学学报（医学版）, 2018, 47(3): 307-312.